Central Trust Company’s ImmunityBio IBRX Stock Holding History

Central Trust Company’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.76K	Hold	1,000	–	–	﹤0.01%	1241
2026 Q1	$7.67K	Hold	1,000	–	–	﹤0.01%	1201
2025 Q4	$1.98K	Hold	1,000	–	–	﹤0.01%	1329
2025 Q3	$2.46K	Hold	1,000	–	–	﹤0.01%	1272
2025 Q2	$2.64K	Hold	1,000	–	–	﹤0.01%	1285
2025 Q1	$3.01K	Hold	1,000	–	–	﹤0.01%	1279
2024 Q4	$2.56K	Hold	1,000	–	–	﹤0.01%	1291
2024 Q3	$3.72K	Hold	1,000	–	–	﹤0.01%	1195
2024 Q2	$6.32K	Hold	1,000	–	–	﹤0.01%	1141
2024 Q1	$5.37K	Hold	1,000	–	–	﹤0.01%	1164
2023 Q4	$5.02K	Buy	+1,000	New	+$3.14K	﹤0.01%	1162

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Central Trust Company's IBRX Position: Q2 2026 in Review

Central Trust Company held its ImmunityBio (IBRX) position steady in Q2 2026 at 1,000 shares worth $8.76K. The position accounts for ﹤0.01% of the portfolio, ranked #1241.

Central Trust Company first reported a position in IBRX in Q4 2023 and has held it in 11 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Central Trust Company held 1,000 shares of ImmunityBio worth $8.76K as of Q2 2026.
Central Trust Company left its ImmunityBio share count unchanged in Q2 2026.
ImmunityBio made up ﹤0.01% of Central Trust Company's portfolio in Q2 2026, its #1241 holding.
Central Trust Company first reported a position in ImmunityBio in Q4 2023 and has held it in 11 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Central Trust Company's 13F filing for Q2 2026, filed 31 Jul 2026.